SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    R. Eming, Pemphigus, Der Hautarzt, 2015, 66, 8, 574

    CrossRef

  2. 2
    M. Hertl, H. Jedlickova, S. Karpati, B. Marinovic, S. Uzun, S. Yayli, D. Mimouni, L. Borradori, C. Feliciani, D. Ioannides, P. Joly, C. Kowalewski, G. Zambruno, D. Zillikens, M.F. Jonkman, Pemphigus. S2 Guideline for diagnosis and treatment – guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Journal of the European Academy of Dermatology and Venereology, 2015, 29, 3
  3. 3
    Rüdiger Eming, Michael Sticherling, Silke C. Hofmann, Nicolas Hunzelmann, Johannes S. Kern, Harald Kramer, Christiane Pfeiffer, Volker Schuster, Detlef Zillikens, Matthias Goebeler, Michael Hertl, Alexander Nast, Hans-Dieter Orzechowski, Miklós Sárdy, Enno Schmidt, Cassian Sitaru, Birte Sporbeck, Margitta Worm, S2k guidelines for the treatment of pemphigus vulgaris/foliaceus and bullous pemphigoid, JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2015, 13, 8
  4. 4
    Rüdiger Eming, Michael Sticherling, Silke C. Hofmann, Nicolas Hunzelmann, Johannes S. Kern, Harald Kramer, Christiane Pfeiffer, Volker Schuster, Detlef Zillikens, Matthias Goebeler, Michael Hertl, Alexander Nast, Hans-Dieter Orzechowski, Miklós Sárdy, Enno Schmidt, Cassian Sitaru, Birte Sporbeck, Margitta Worm, S2k-Leitlinie zur Therapie des Pemphigus vulgaris/foliaceus und des bullösen Pemphigoid, JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2015, 13, 8
  5. 5
    Gudula Kirtschig, Christof Schaefer, Drugs During Pregnancy and Lactation, 2015,

    CrossRef

  6. 6
    M. Kolesnik, E. Becker, D. Reinhold, A. Ambach, M.U. Heim, H. Gollnick, B. Bonnekoh, Treatment of severe autoimmune blistering skin diseases with combination of protein A immunoadsorption and rituximab: a protocol without initial high dose or pulse steroid medication, Journal of the European Academy of Dermatology and Venereology, 2014, 28, 6
  7. 7
    Balighi Kamran, Daneshpazhooh Maryam, Khezri Somayeh, Mahdavi-nia Mostafa, Hajiseyed-javadi Mahsa, Chams-Davatchi Cheyda, Adjuvant rituximab in the treatment of pemphigus vulgaris: a phase II clinical trial, International Journal of Dermatology, 2013, 52, 7
  8. 8
    ID O’Neill, C Scully, Biologics in oral medicine: ulcerative disorders, Oral Diseases, 2013, 19, 1
  9. 9
    Christoph M Hammers, Luisa Lunardon, Enno Schmidt, Detlef Zillikens, Contemporary management of pemphigus, Expert Opinion on Orphan Drugs, 2013, 1, 4, 295

    CrossRef

  10. 10
    Bianka Sobolewska, Christoph Deuter, Manfred Zierhut, Current Medical Treatment of Ocular Mucous Membrane Pemphigoid, The Ocular Surface, 2013, 11, 4, 259

    CrossRef

  11. 11
    A.J. Kanwar, D. Tsuruta, K. Vinay, H. Koga, N. Ishii, T. Dainichi, T. Hashimoto, Efficacy and safety of rituximab treatment in Indian pemphigus patients, Journal of the European Academy of Dermatology and Venereology, 2013, 27, 1
  12. 12
    J.H. Kim, S.-C. Kim, Epidermolysis bullosa acquisita, Journal of the European Academy of Dermatology and Venereology, 2013, 27, 10
  13. 13
    Angeline Anning Yong, Hong Liang Tey, Paraneoplastic pemphigus, Australasian Journal of Dermatology, 2013, 54, 4
  14. 14
    L. Vanstreels, A. Alkhateeb, M. Megahed, Pemphigus vulgaris, Der Hautarzt, 2013, 64, 5, 330

    CrossRef

  15. 15
    A. España, E. Ornilla, C. Panizo, Rituximab en dermatología, Actas Dermo-Sifiliográficas, 2013, 104, 5, 380

    CrossRef

  16. 16
    A. España, E. Ornilla, C. Panizo, Rituximab in dermatology, Actas Dermo-Sifiliográficas (English Edition), 2013, 104, 5, 380

    CrossRef

  17. 17
    Yael A. Leshem, Emmilia Hodak, Michael David, Grant J. Anhalt, Daniel Mimouni, Successful treatment of pemphigus with biweekly 1-g infusions of rituximab: A retrospective study of 47 patients, Journal of the American Academy of Dermatology, 2013, 68, 3, 404

    CrossRef

  18. 18
    Mónica Lorente Luna, Adriana Juanes Viedma, Adrián Ballano Ruiz, Paulina Belmar Flores, Jesús Cuevas Santos, Esther de Eusebio Murillo, Tratamiento del pénfigo vulgar con rituximab, Piel, 2013, 28, 6, 326

    CrossRef

  19. 19
    Michael Sticherling, Cornelia Erfurt-Berge, Autoimmune blistering diseases of the skin, Autoimmunity Reviews, 2012, 11, 3, 226

    CrossRef

  20. You have free access to this content20
    ID O’Neill, C Scully, Biologics in oral medicine: principles of use and practical considerations, Oral Diseases, 2012, 18, 6
  21. 21
    M. Behzad, C. Möbs, A. Kneisel, M. Möller, J. Hoyer, M. Hertl, R. Eming, Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris, British Journal of Dermatology, 2012, 166, 4
  22. 22
    Michael Kasperkiewicz, Enno Schmidt, Detlef Zillikens, Current therapy of the pemphigus group, Clinics in Dermatology, 2012, 30, 1, 84

    CrossRef

  23. 23
    Michael Kasperkiewicz, Rüdiger Eming, Melika Behzad, Nicolas Hunzelmann, Michael Meurer, Hendrik Schulze-Koops, Peter von Wussow, Michael Hertl, Detlef Zillikens, Klaus Freivogel, Thomas Dörner, Enno Schmidt, Efficacy and safety of rituximab in pemphigus: experience of the German Registry of Autoimmune Diseases, JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2012, 10, 10
  24. 24
    Michael Meurer, Immunosuppressive therapy for autoimmune bullous diseases, Clinics in Dermatology, 2012, 30, 1, 78

    CrossRef

  25. 25
    B. Horváth, J. Huizinga, H.H. Pas, A.B. Mulder, M.F. Jonkman, Low-dose rituximab is effective in pemphigus, British Journal of Dermatology, 2012, 166, 2
  26. 26
    Michael Kasperkiewicz, Detlef Zillikens, Enno Schmidt, Pemphigoid diseases: Pathogenesis, diagnosis, and treatment, Autoimmunity, 2012, 45, 1, 55

    CrossRef

  27. 27
    Donna A. Culton, Luis A. Diaz, Treatment of subepidermal immunobullous diseases, Clinics in Dermatology, 2012, 30, 1, 95

    CrossRef

  28. 28
    N Cirillo, E Cozzani, M Carrozzo, SA Grando, Urban legends: pemphigus vulgaris, Oral Diseases, 2012, 18, 5
  29. 29
    Klinische Immunologie, 2012,

    CrossRef

  30. 30
    Martin Laimer, Gabriela Pohla-Gubo, Lukas Kraus, Elke Nischler, J.W. Bauer, V. Ahlgrimm-Siess, Helmut Hintner, Autoimmune Bullous Diseases in Austria, Dermatologic Clinics, 2011, 29, 4, 691

    CrossRef

  31. 31
    Andrea Kneisel, Michael Hertl, Autoimmune bullous skin diseases. Part 2: diagnosis and therapy, JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2011, 9, 11
  32. 32
    J.H. Kim, Y.H. Kim, M.R. Kim, S.-C. Kim, Clinical efficacy of different doses of rituximab in the treatment of pemphigus: a retrospective study of 27 patients, British Journal of Dermatology, 2011, 165, 3
  33. 33
    Enno Schmidt, Detlef Zillikens, Diagnosis and Treatment of Patients with Autoimmune Bullous Disorders in Germany, Dermatologic Clinics, 2011, 29, 4, 663

    CrossRef

  34. 34
    Fa-Chyi Lee, Longterm clinical remission of oral and cutaneous pemphigus with thalidomide, International Journal of Dermatology, 2011, 50, 9
  35. 35
    In-Ho Song, Denis Poddubnyy, New treatment targets in ankylosing spondylitis and other spondyloarthritides, Current Opinion in Rheumatology, 2011, 23, 4, 346

    CrossRef

  36. 36
    Cheyda Chams-Davatchi, Prevalence and Treatment of Pemphigus in Iran, Dermatologic Clinics, 2011, 29, 4, 681

    CrossRef

  37. 37
    Ron J Feldman, A Razzaque Ahmed, Relevance of rituximab therapy in pemphigus vulgaris: analysis of current data and the immunologic basis for its observed responses, Expert Review of Clinical Immunology, 2011, 7, 4, 529

    CrossRef

  38. 38
    Michael Marker, Kurt Derfler, Babak Monshi, Klemens Rappersberger, Successful immunoapheresis of bullous autoimmune diseases: pemphigus vulgaris and pemphigoid gestationis, JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2011, 9, 1
  39. 39
    Yaohan Li, J.B. Foshee, Richard D. Sontheimer, Sustained clinical response to rituximab in a case of life-threatening overlap subepidermal autoimmune blistering disease, Journal of the American Academy of Dermatology, 2011, 64, 4, 773

    CrossRef

  40. 40
    A. Recke, I. Shimanovich, P. Steven, L. Westermann, D. Zillikens, E. Schmidt, Therapieresistentes Anti-Laminin-332-Schleimhautpemphigoid, Der Hautarzt, 2011, 62, 11, 852

    CrossRef

  41. 41
    Janelle Vega, David A Rodriguez, Treatments for Skin of Color, 2011,

    CrossRef

  42. 42
    Jutta Zimmermann, Friedrich Bahmer, Christian Rose, Detlef Zillikens, Enno Schmidt, Clinical and immunopathological spectrum of paraneoplastic pemphigus, JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2010, 8, 8
  43. You have free access to this content43
    Thomas Lindebo Holm, Helle Markholst, Confirmation of a disease model of pemphigus vulgaris: characterization and correlation between disease parameters in 90 mice, Experimental Dermatology, 2010, 19, 8
  44. 44
    I.-H. Song, F. Heldmann, M. Rudwaleit, J. Listing, H. Appel, J. Braun, J. Sieper, Different response to rituximab in tumor necrosis factor blocker–naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: A twenty-four–week clinical trial, Arthritis & Rheumatism, 2010, 62, 5
  45. 45
    Norito Ishii, Takashi Hashimoto, Detlef Zillikens, Ralf J. Ludwig, High-Dose Intravenous Immunoglobulin (IVIG) Therapy in Autoimmune Skin Blistering Diseases, Clinical Reviews in Allergy & Immunology, 2010, 38, 2-3, 186

    CrossRef

  46. 46
    Nuno Menezes, Inês Leite, David Tente, António Couceiro, Armando Baptista, Paulo Varela, Pemphigus vulgaris – still a difficult disease to treat, International Journal of Dermatology, 2010, 49, 2
  47. 47
    Ralf Müller, Nicolas Hunzelmann, Vera Baur, Guido Siebenhaar, Elke Wenzel, Rüdiger Eming, Andrea Niedermeier, Philippe Musette, Pascal Joly, Michael Hertl, Targeted Immunotherapy with Rituximab Leads to a Transient Alteration of the IgG Autoantibody Profile in Pemphigus Vulgaris, Dermatology Research and Practice, 2010, 2010, 1

    CrossRef

  48. 48
    Angela Nagel, Michael Hertl, Rüdiger Eming, B-Cell-Directed Therapy for Inflammatory Skin Diseases, Journal of Investigative Dermatology, 2009, 129, 2, 289

    CrossRef

  49. 49
    M. Alter, M. Wittmann, B. Völker, A. Kapp, T. Werfel, R. Gutzmer, Erfolgreiche Therapie des Pemphigus foliaceus mit Rituximab, Der Hautarzt, 2009, 60, 9, 743

    CrossRef

  50. 50
    Silke C. Hofmann, Ocko Kautz, Michael Hertl, Michael Sticherling, Detlef Zillikens, Leena Bruckner-Tuderman, Results of a survey of German dermatologists on the therapeutic approaches to pemphigus and bullous pemphigoid, JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2009, 7, 3
  51. 51
    Enno Schmidt, Matthias Goebeler, Detlef Zillikens, Rituximab in Severe Pemphigus, Annals of the New York Academy of Sciences, 2009, 1173, 1
  52. 52
    M. Laimer, C.M. Lanschützer, M. Emberger, E. Nischler, J. Stoiber, H. Hintner, Schleimhautbeteiligung bei blasenbildenden Erkrankungen, Der Hautarzt, 2009, 60, 11, 881

    CrossRef

  53. 53
    E. Schmidt, Therapieoptimierung bei schweren bullösen Autoimmundermatosen, Der Hautarzt, 2009, 60, 8, 633

    CrossRef

  54. 54
    Enno Schmidt, Matthias Goebeler, CD20-directed therapy in autoimmune diseases involving the skin: role of rituximab, Expert Review of Dermatology, 2008, 3, 3, 259

    CrossRef

  55. 55
    A. Nagel, M. Hertl, R. Eming, Einsatz B-Zell-depletierender Antikörper bei Hauterkrankungen, Der Hautarzt, 2008, 59, 10, 793

    CrossRef

  56. 56
    Gudula Kirtschig, Philippa Middleton, Cathy Bennett, Dedee F Murrell, Fenella Wojnarowska, Nonhlanhla P Khumalo, Interventions for bullous pemphigoid, The Cochrane Library,